Assessment of a Protocol Using a Combination of Neo-adjuvant Chemotherapy Plus Living Donor Liver Transplantation for Non-Resectable Liver Metastases From Colorectal Cancer
Patients with unresectable liver metastases (LM) from colorectal cancer (CRC)have a poor
prognosis. In patients with resectable disease, surgery offers a distinct survival benefit.
This study will offer live donor liver transplantation (LDLT) to select patients with
unresectable metastases that are 1) limited to the liver and 2) stable (non-progressing) on
standard chemotherapy. Potential participants will be evaluated for liver transplant
suitability and must also have a willing, healthy living donor come forward for evaluation.
Those participants who undergo LDLT will be followed for survival, disease-free survival and
quality of life for 5 years and compared to a "control group" of participants who drop out
of study prior to transplantation due to reasons other than cancer progression.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society